aminoisobutyric acid raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
As of August 2018, pembrolizumab is indicated for the treatment of those with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. In November 2018, the US FDA granted accelerated approval to pembrolizumab for those with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. In February 2019, the US FDA approved pembrolizumab for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. The FDA granted the application orphan drug designation. In June 2019, the US FDA granted accelerated approval to pembrolizumab for those with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy, and the FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Pembrolizumab was approved for use in combination with platinum and fluorouracil (FU) for all patients and as a single agent for patients whose tumors express PD‑L1 (Combined Positive Score [CPS] ≥ 1) as determined by an FDA‑approved test.
==== Academic licencing, licence steering and AI commercialisation ==== The use of academic research for Large Language Models (LLMs) has sparked debate within the Open Access movement. Academics accuse publishers of steering authors towards restrictive licences to retain exclusive commercial rights for AI training deals. In 2024, publishers like Taylor & Francis announced lucrative AI training partnerships, often without consulting authors. This dynamic complicates copyright litigation, as seen in the US when Elsevier sued Meta over Llama AI models, acting as the class representative due to exclusive commercial rights granted by authors.
Almost exclusively affects women. Starts or worsens at times of hormonal changes: puberty, pregnancy, or menopause. Bilateral, symmetrical buildup of fat in the legs, and sometimes arms and lower trunk, that is resistant to nutritional intervention, exercise, elevation, diuretics, and bariatric surgery. Feet/hands are typically spared, presenting with a raised ridge or fold of fat. In earlier stages, there may be a subtle, raised ridge or fold of fat instead of distinct cuffing to the ankle or wrist. Sometimes, especially in later stages, this increased adipose tissue above the ankle/wrist can cause the appearance of a “cuff” (“pantaloons” is an evocative term sometimes to describe this morphology in later stages). Presence of nodular and/or fibrotic texture beneath the skin, which can create an uneven, dimpled appearance. Complaints of pain, tenderness, and/or heaviness in affected areas. Fatigue, brain fog, easy bruising. Edema and joint hypermobility may also be present. Texture and visual presentation may change with swelling and inflammation.
== Statistics == From 1992 to 2009, Memphis International was the world's busiest airport for cargo operations. It dropped to second place in 2010, just behind Hong Kong. It still remained the busiest cargo airport in the United States and the Western Hemisphere. It briefly rose to first place once again in 2020, due to the surge in e-commerce partly caused by the COVID-19 pandemic, but dropped back to second place in 2021.
In non-small cell lung cancer, both mRNA and protein levels of TMPRSS11D are elevated in tumor tissue compared with adjacent normal tissue, and high protein expression is an independent predictor of poorer overall survival. Plasminogen (PLG), from which originates the mini-plasmin that can cleave the F-protein, is highly expressed in liver cancers. Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal liver and in liver cancers. SeV constructs were created with a modified protease cleavage site. The modification allowed the recombinant virus to specifically infect cancer cells that expressed the corresponding proteases, which can cleave a modified protease cleavage site.
Sources: en.wikipedia.org
=== Systematics === The emu was long classified, with its closest relatives the cassowaries, in the family Casuariidae, part of the ratite order Struthioniformes. An alternate classification was proposed in 2014 by Mitchell et al., based on analysis of mitochondrial DNA. This splits off the Casuariidae into their own order, the Casuariiformes, and includes only the cassowaries in the family Casuariidae, placing the emus in their own family, Dromaiidae. The cladogram shown below is from their study.
Building automation, access control, smart energy — DASH7's signal propagation characteristics allow it to penetrate walls, windows, doors, and other substances that serve as impediments to other technologies operating at 2.45 GHz, for example. For smart energy and building automation applications, DASH7 networks can be deployed with far less infrastructure than competing technologies and at far lower total cost of ownership. Location-based services — DASH7 is being used today for developing new location-based services using a range of DASH7-enabled devices, including smartcards, keyfobs, tickets, watches and other conventional products that can take advantage of the unique small footprint, low power, long range, and low cost of DASH7 relative to less practical and high-power wireless technologies like Wi-Fi or Bluetooth. Using DASH7, users can "check in" to venues in ways not practical with current check-in technologies like GPS, that are power-intensive and fail indoors and in urban environments. Location-based services like Foursquare, Novitaz, or Facebook can exploit this capability in DASH7 and award loyalty points, allow users to view the Facebook or X, formally known as Twitter, addresses of those walking past, and more. Mobile advertising — DASH7 is being developed for "smart" billboards and kiosks, likewise "smart" posters that can be read from many meters (or even kilometers) away, creating new opportunities for both tracking the effectiveness of advertising expenditures, but also creating new e-commerce opportunities.
Cohen (1955): working class teenagers joined gangs due to frustration of inability to achieve status and goals of the middle class; Cloward and Ohlin (1960): blocked opportunity, but unequal distribution of opportunities lead to creating different types of gangs (that is, some focused on robbery and property theft, some on fighting and conflict and some were retreatists focusing on drug taking); Spergel (1966) was one of the first criminologists to focus on evidence-based practice rather than intuition into gang life and culture. Participation in gang-related events during adolescence perpetuate a pattern of maltreatment on their own children years later. Klein (1971) like Spergel studied the effects on members of social workers' interventions. More interventions actually lead to greater gang participation and solidarity and bonds between members. Downes and Rock (1988) on Parker's analysis: strain theory applies, labeling theory (from experience with police and courts), control theory (involvement in trouble from early childhood and the eventual decision that the costs outweigh the benefits) and conflict theories. No ethnic group is more disposed to gang involvement than another, rather it is the status of being marginalized, alienated or rejected that makes some groups more vulnerable to gang formation, and this would also be accounted for in the effect of social exclusion, especially in terms of recruitment and retention. These may also be defined by age (typically youth) or peer group influences, and the permanence or consistency of their criminal activity.
=== Effect on the immune microenvironment === CAFs can produce cytokine TGF-β which has inhibitory effect on T cells, macrophages and neutrophils thus they are not able to promote immune response against the tumor. Immune system is greatly affected by CAFs. CAFs promote the recruitment of monocytes and induce their differentiation into pro-tumorigenic macrophage subset M2. In breast cancer secretion of monocyte chemotactic protein-1, stromal-derived factor 1 and chitinase 3-like 1 is a signal for monocyte migration and differentiation into M2 subset. Similar effect was observed in prostate carcinoma. In pancreatic cancer, other cytokines have central role in monocyte differentiation into M2 subset such as M-CSF1, IL-6 and CCL2. Other cytokines such as IL-8, IL-10, TGF-β also participate. Such M2 macrophages then further activate progression of CAFs. CAFs have inhibitory effects on NK cells by releasing prostaglandin E2 (PGE2). In hepatocellular carcinoma besides PGE2, indoleamine 2,3-dioxygenase (IDO) is suppressing NK cells. In the restriction of anti-tumor immunity are crucial regulatory T cells (Treg; Foxp3+). CAFs stimulate migration, induction and maintenance of Treg cells which depends on the chemokines CCL5 and CXCL12. Critical for anti-tumor immunity are cytotoxic CD8+ T cells. CAFs decrease their infiltration into tumor by releasing chemokine CXCL12 and cytokines IL-6 and TGF-β. However, for T cell movement restriction in tumors is also responsible hypoxia, which leads to decrease of expression of adhesion molecules on endothelial cells.
Sources: en.wikipedia.org
A more recent application of bone grafting is its use as an antibiotic carrier. Infected bone is poorly perfused, making it difficult to achieve an appropriate antibiotic concentration at the site of infection when intravenous administration is used, especially for antibiotics with large molecules such as vancomycin. In such cases, impacted morcellized bone allografts (IBG), impregnated with local antibiotics can achieve much higher concentrations of antibiotics locally than the minimum inhibitory concentration (MIC).
Itopride (INN; brand name Ganaton) is a prokinetic benzamide derivative. These drugs inhibit dopamine and acetylcholine esterase enzyme and have a gastrokinetic effect. Itopride is indicated for the treatment of functional dyspepsia and other gastrointestinal conditions. It is a combined D2 receptor antagonist and acetylcholinesterase inhibitor. Itopride is the dimethoxy analog of trimethobenzamide.
Factor VIII was first characterized in 1984 by scientists at Genentech. The gene for factor VIII is located on the X chromosome (Xq28). The gene for factor VIII presents an interesting primary structure, as another gene (F8A1) is embedded in one of its introns.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.